Charles Schwab Investment Management Inc. Has $3.31 Million Stock Position in Celcuity Inc. (NASDAQ:CELC)

Charles Schwab Investment Management Inc. grew its stake in shares of Celcuity Inc. (NASDAQ:CELC) by 226.2% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 221,671 shares of the company’s stock after buying an additional 153,712 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Celcuity were worth $3,305,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Samlyn Capital LLC boosted its holdings in shares of Celcuity by 92.4% during the 2nd quarter. Samlyn Capital LLC now owns 1,326,953 shares of the company’s stock valued at $21,735,000 after acquiring an additional 637,190 shares in the last quarter. Driehaus Capital Management LLC raised its position in Celcuity by 62.3% in the second quarter. Driehaus Capital Management LLC now owns 204,592 shares of the company’s stock valued at $3,351,000 after purchasing an additional 78,525 shares during the last quarter. Marshall Wace LLP boosted its stake in shares of Celcuity by 40.0% during the second quarter. Marshall Wace LLP now owns 152,291 shares of the company’s stock valued at $2,495,000 after purchasing an additional 43,476 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its holdings in shares of Celcuity by 34.7% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 73,026 shares of the company’s stock worth $1,089,000 after purchasing an additional 18,809 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Celcuity by 42.7% in the second quarter. Bank of New York Mellon Corp now owns 66,256 shares of the company’s stock valued at $1,085,000 after buying an additional 19,811 shares during the period. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently commented on CELC shares. Lifesci Capital started coverage on shares of Celcuity in a research report on Monday, August 26th. They set an “outperform” rating and a $27.00 target price on the stock. Stifel Nicolaus lifted their price target on shares of Celcuity from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Monday, October 7th. HC Wainwright reissued a “buy” rating and issued a $27.00 price objective on shares of Celcuity in a research note on Friday, November 15th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 target price on shares of Celcuity in a research report on Friday, November 15th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Celcuity presently has an average rating of “Buy” and a consensus price target of $29.17.

Celcuity Price Performance

Shares of NASDAQ CELC opened at $12.52 on Friday. The company has a market capitalization of $464.87 million, a PE ratio of -4.80 and a beta of 0.74. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65. Celcuity Inc. has a twelve month low of $11.51 and a twelve month high of $22.19. The firm has a fifty day simple moving average of $14.34 and a 200 day simple moving average of $15.48.

Celcuity Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.